BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Invitrogen Corporation (IVGN) Signs Definitive Agreement To Acquire BioSource International, Inc. (BIOI); Deal Strengthens Proteomics Franchise And Positions The Company To Enter New Markets; $130 Million


10/19/2005 5:09:00 PM

CARLSBAD, Calif.--(BUSINESS WIRE)--July 26, 2005--Invitrogen Corporation (Nasdaq:IVGN) today announced the signing of a definitive agreement to acquire publicly held life sciences company BioSource International (Nasdaq:BIOI) in an all-cash transaction totaling approximately $130 million. The transaction is subject to customary closing conditions, including regulatory approval and the approval of BioSource stockholders. The transaction is expected to close by the end of the year. This deal augments Invitrogen's growing collection of protein and primary antibody products gained through its recent acquisitions of Zymed Laboratories and Caltag Laboratories. Additionally, it bolsters Invitrogen's offerings in both kinase and cytokine assay technologies for research applications and provides the company an opportunity to enter new markets in immunology, oncology and neurodegenerative disease.

Read at Reuters
Read at AP
Read at BioSpace.com
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->